No current GLP-1 label lists high blood pressure as an approved use, so prescribing one for it would be off-label. Three STEP trials, pooled (Semaglutide 2.4 mg): Top blood pressure number fell 4.95 mmHg more than on placebo over 68 weeks, and much the same in people with high blood pressure (4.78 mmHg). The authors say weight loss explained much of it, and that part of the result may be because people cut back their blood pressure medicines. The trials were testing weight loss, not a treatment for high blood pressure. ClinicalTrials.gov lists 29 trials of these medicines on it: 4 with posted results and 8 recruiting now.
Read from the registry and PubMed every day. The newest update here is Nov 5, 2026.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide 2.4 mg · 3,136 people · Better than the comparison · Meta-analysis
Top blood pressure number fell 4.95 mmHg more than on placebo over 68 weeks, and much the same in people with high blood pressure (4.78 mmHg). The authors say weight loss explained much of it, and that part of the result may be because people cut back their blood pressure medicines. The trials were testing weight loss, not a treatment for high blood pressure.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 9 | 0 | 4 |
| Liraglutide | 5 | 1 | 0 |
| Orforglipron | 4 | 0 | 1 |
| Tirzepatide | 4 | 0 | 2 |
| Dulaglutide | 3 | 2 | 0 |
| Exenatide | 2 | 1 | 0 |
| Mazdutide | 2 | 0 | 1 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| IIH EVOLVEA Trial to Determine the Efficacy and Safety of Presendin in IIH | Exenatide | Phase 3 | 14 | On ClinicalTrials.gov |
| NCT02299388To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study | Liraglutide | Phase 4 | 11 | On ClinicalTrials.gov |
| NCT01149421A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes | Dulaglutide | Phase 2 | 755 | On ClinicalTrials.gov |
| NCT01324388A Study of the Effect of LY2189265 on Two Blood Pressure Drugs | Dulaglutide | Phase 1 | 51 | On ClinicalTrials.gov |
The registry page names each site and who can enroll. Ask your clinician before joining one.
Written from each source's own record as it changes. Every change on GLPcompare
Three STEP trials, pooled (Semaglutide 2.4 mg, 3,136 people): Top blood pressure number fell 4.95 mmHg more than on placebo over 68 weeks, and much the same in people with high blood pressure (4.78 mmHg). The authors say weight loss explained much of it, and that part of the result may be because people cut back their blood pressure medicines. The trials were testing weight loss, not a treatment for high blood pressure.
Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.
Semaglutide, with 9 registered trials on it, then Liraglutide with 5. More trials do not mean better results: read what each posted.
8 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.